The concomitant usage of buprenorphine and CYP3A4 inducers can decrease the plasma concentration of buprenorphine [see CLINICAL PHARMACOLOGY], likely leading to reduced efficacy or onset of the withdrawal syndrome in people who have produced physical dependence to buprenorphine.The knowledge offered in this site is intended to complement, not subst